Understand the mechanisms being studied, the evidence available, and the questions that remain open.
OtherEpitalon is a synthetic tetrapeptide often discussed in longevity research. Its association with telomeres has led to broad online claims about slowing aging. The ability to change a laboratory marker is much narrower than proof that a treatment extends healthy human life.
OtherFOXO4-DRI is an experimental peptide investigated as a senolytic approach. Senolytics aim to selectively remove certain senescent cells. This research concept is not the same as proof that a consumer product reverses human aging or safely improves health in otherwise healthy adults.
OtherNAD+ is a coenzyme involved in cellular metabolism, not a peptide. It appears in many peptide-oriented catalogs because of interest in wellness and aging. Keeping that classification clear prevents readers from assuming that all compounds in a catalog share the same chemistry or clinical evidence.
OtherPT-141 is a research name associated with bremelanotide. An FDA-approved bremelanotide product, Vyleesi, is indicated for a defined form of hypoactive sexual desire disorder in premenopausal women. It is not a general sexual-performance enhancer and its evidence should not be generalized to all people with low desire.
OtherSS-31 is a development name for elamipretide, a mitochondria-targeting peptide. In September 2025, FDA granted accelerated approval to Forzinity for improving muscle strength in adults and children with Barth syndrome who weigh at least 30 kilograms. This specific approval does not establish a general anti-aging indication.
| Compound | Research topic | Overview | Guide |
|---|---|---|---|
| Epitalon | Other | Epitalon is a synthetic tetrapeptide often discussed in longevity research. Its association with telomeres has led to broad online claims about slowing aging. The ability to change a laboratory marker is much narrower than proof that a treatment extends healthy human life. | Read ↗ |
| FOXO4-DRI | Other | FOXO4-DRI is an experimental peptide investigated as a senolytic approach. Senolytics aim to selectively remove certain senescent cells. This research concept is not the same as proof that a consumer product reverses human aging or safely improves health in otherwise healthy adults. | Read ↗ |
| NAD+ | Other | NAD+ is a coenzyme involved in cellular metabolism, not a peptide. It appears in many peptide-oriented catalogs because of interest in wellness and aging. Keeping that classification clear prevents readers from assuming that all compounds in a catalog share the same chemistry or clinical evidence. | Read ↗ |
| PT-141 | Other | PT-141 is a research name associated with bremelanotide. An FDA-approved bremelanotide product, Vyleesi, is indicated for a defined form of hypoactive sexual desire disorder in premenopausal women. It is not a general sexual-performance enhancer and its evidence should not be generalized to all people with low desire. | Read ↗ |
| SS-31 | Other | SS-31 is a development name for elamipretide, a mitochondria-targeting peptide. In September 2025, FDA granted accelerated approval to Forzinity for improving muscle strength in adults and children with Barth syndrome who weigh at least 30 kilograms. This specific approval does not establish a general anti-aging indication. | Read ↗ |